UK doctors win battle with drug giants over cheaper eye medi
The NHS has won a legal battle against the pharmaceutical industry (drug giants Novartis, Bayer and Roche) which will lead to patients with the most common form of blindness receiving a drug that is much cheaper but still very effective.

The high court backed a bid by 12 NHS clinical commissioning groups (CCG) in the north-east of England to give Avastin to people with worsening sight loss.

Though typically used to treat cancer, Avastin has also been proven to help tackle wet age-related macular degeneration (AMD). The decision could help the NHS save more than £100m (~950+ Cr) a year because Avastin is 30 times cheaper than the two existing treatments, Lucentis and Eylea.

The court backed the 12 CCGs, even though Avastin has only been licensed in the UK to treat cancer and not AMD. However, private hospitals in Britain use Avastin as their main treatment for AMD and the drug has also been widely used in the US and other countries for that purpose.

Read more: